Chongqing Pharscin Pharmaceutical Co., Ltd. Stock price

Equities

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
13.99 CNY +0.36% Intraday chart for Chongqing Pharscin Pharmaceutical Co., Ltd. -7.72% -9.45%
Sales 2021 846M 117M Sales 2022 785M 109M Capitalization 8.5B 1.18B
Net income 2021 91M 12.61M Net income 2022 98M 13.58M EV / Sales 2021 8.26 x
Net cash position 2021 259M 35.94M Net cash position 2022 503M 69.73M EV / Sales 2022 10.2 x
P/E ratio 2021
78.9 x
P/E ratio 2022
83.4 x
Employees 1,416
Yield 2021
0.28%
Yield 2022
0.34%
Free-Float 18.33%
More Fundamentals * Assessed data
Dynamic Chart
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules MT
Pharscin Pharma's Production Base Passes US FDA Inspection MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements Final Cash Dividend of A shares for 2022, Payable on June 13, 2023 CI
Chongqing Pharscin Pharmaceutical Co., Ltd Approves the Cash Dividend for 2022 CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4% MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue MT
Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
More news
1 day+0.36%
1 week-7.72%
Current month+2.79%
1 month+5.19%
3 months-8.38%
6 months-20.06%
Current year-9.45%
More quotes
1 week
13.68
Extreme 13.68
14.79
1 month
13.35
Extreme 13.35
15.71
Current year
9.82
Extreme 9.82
17.43
1 year
9.82
Extreme 9.82
20.50
3 years
9.82
Extreme 9.82
34.85
5 years
9.82
Extreme 9.82
34.85
10 years
5.98
Extreme 5.98
47.92
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-08-18
Chairman 58 00-09-30
Director of Finance/CFO 50 02-02-28
Members of the board TitleAgeSince
Director/Board Member 58 22-05-17
Chairman 61 15-08-18
Chief Executive Officer 61 15-08-18
More insiders
Date Price Change Volume
24-03-29 14.02 +0.21% 1,944,200
24-03-28 13.99 +0.36% 3,697,397
24-03-27 13.94 -2.11% 4,590,245
24-03-26 14.24 -0.70% 3,258,800
24-03-25 14.34 -2.38% 3,164,770

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company's products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Chongqing Pharscin Pharmaceutical Co., Ltd. - Shenzhen S.E.